blinatumomab (Blincyto®)

Reference No. 589

Appraisal information

blinatumomab (Blincyto®) 38.5 microgram/vial powder for concentrate and solution for solution for infusion

Company:

Amgen Ltd

BNF category:

Malignant disease and immunosupression

NMG meeting date:

08/06/2016

AWMSG meeting date:

13/07/2016

Submission Type:

Full Submission

Status:

Superseded

Advice No:

1916

Ministerial ratification:

26/07/2016

Current Progress

Submission received

NMG meeting

AWMSG meeting

Ministerial Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA450)
NICE GUIDANCE ISSUED JUNE 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)